Pharmaceutical Executive October 8, 2025
Mike Hollan, William Soliman, PhD

Pharma companies have the choice of facing strict tariffs or negotiating with the current administration.

Pharmaceutical Executive: How will pharma companies react to the administration’s efforts?
Dr. William Soliman: We’ve seen Pfizer doing a deal with Trump, and I think other companies will follow. If they can come to a compromise for even just some branded drugs, that’s a happy middle-ground. What they’re looking for in exchange for dropping prices is for the administration to push back the tariffs. That’s part of the Pfizer deal.

I do think it will make a difference and pharma companies will concede, even if not fully to what Trump wants. Even if it’s a little bit, that’s still better than nothing.

PE: What is the...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Congress / White House, Govt Agencies, Interview / Q&A, Pharma, Pharma / Biotech, Trends
Q&A: New PQA Resource Highlights 40 Projects Targeting Social Determinants of Health
NVIDIA and Lilly Announce Co-Innovation AI Lab to Accelerate Drug Discovery
The Future of Pharmacovigilance Technology: How AI and Automation Are Redefining Drug Safety
CVS accused of shutting out rival pharmacy hubs in House Judiciary investigation
Mirum Pharmaceuticals Completes $268.6 Million Acquisition of Bluejay Therapeutics to Strengthen Rare Disease Pipeline

Share Article